Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program

ANVISA (Brazilian Health Authority) approved Biophytis' Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care UnitSarconeos (BIO101)

Related Keywords

Veillet ,Rhôalpes ,France ,Sao Paulo ,Sãpaulo ,Brazil ,United States ,Paris ,France General ,Massachusetts ,Cambridge ,Cambridgeshire ,United Kingdom ,America ,Brazilian ,American ,Agathe Boggio ,Suzana Lobo ,Evelyne Nguyen ,Antoine Denry ,Ludhmila Hajjar ,Hospital De ,Exchange Commission ,Anvisa Brazilian Health Authority ,Sorbonne University ,Biophyti Expanded Access Program ,Care Division ,Access Program ,Brazilian Health Authority ,Intensive Care ,Intensive Care Units ,Latin America ,Euronext Growth Paris ,Expanded Access Program ,Intensive Care Unit ,Principal Investigator ,Intensive Care Division ,Duchenne Muscular Dystrophy ,Euronext Growth ,American Depositary Shares ,Year Report ,Biophytis ,Eceived ,Approval ,Rom ,Anvisa ,Five ,Access ,Sarconeos ,Io101 ,Hospitalized ,Covid ,Patients ,Through ,Xpanded ,Program ,